Evidence map›Paper›PMID 34987505›Full record

ArticleFrontiers in immunology2021

Detection of Antibody Responses Against SARS-CoV-2 in Plasma and Saliva From Vaccinated and Infected Individuals.

Jéromine Klingler, Gregory S Lambert, Vincenza Itri, Sean Liu, Juan C Bandres, Gospel Enyindah-Asonye, Xiaomei Liu, Viviana Simon, Charles R Gleason, Giulio Kleiner and 8 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. COVID-19 vaccines: current and future challenges.Frontiers in pharmacology · 2024
    Review
  11. Article
  12. Infectious virus shedding duration reflects secretory IgA antibody response latency after SARS-CoV-2 infection.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 1 country.

Jéromine KlinglerDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Gregory S LambertDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Vincenza ItriDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Sean LiuDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Juan C BandresDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Gospel Enyindah-AsonyeDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Xiaomei LiuDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Viviana SimonDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Charles R GleasonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Giulio KleinerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Hsin-Ping ChiuDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Chuan-Tien HungDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Shreyas KowdleDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Fatima AmanatDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Benhur LeeDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Susan Zolla-PaznerDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Chitra UpadhyayDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Catarina E HioeDivision of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Icahn School of Medicine at Mount Sinai · USJames J. Peters VA Medical Center · US

Funding

Programming Durable Immune Responses To VaccinationU01AI141990 · NIAID · WASHINGTON UNIVERSITY · PI Ali Hassan Ellebedy · 2019 to 2026
$5.3M
Harnessing Abs specific for immunogenic and conserved Env epitopes to protect against HIVR01AI139290 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HIOE, CATARINA E · 2018 to 2022
$4.1M
Modulating antigenic and immunogenic properties of HIV Env by altering signal sequenceR01AI140909 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI UPADHYAY, CHITRA · 2019 to 2023
$3.3M
Tropism, pathogenicity, and potential for zoonotic spillover of emergent henipa- and henipa-like virusesR01AI123449 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI LEE, BENHUR · 2016 to 2020
$2.7M
A Decision Making Framework for Contralateral Prophylactic MastectomyR21CA149803 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BREWSTER, ABENAA M, PARKER, PATRICIA A · 2010 to 2011
$372k
Understanding Th-monocyte interactions in HIV infectionI01BX003860 · VA · JAMES J PETERS VA MEDICAL CENTER · PI HIOE, CATARINA E · 2018 to 2021
–
BLR&D Research Career Scientist Award ApplicationIK6BX004607 · VA · JAMES J PETERS VA MEDICAL CENTER · PI HIOE, CATARINA E · 2019 to 2025
–
BLRD VA I01 BX003860BLRD VA I01 BX005794BLRD VA IK6 BX004607NCI NIH HHS R21 CA149803NIAID NIH HHS R01 AI123449NIAID NIH HHS R01 AI139290NIAID NIH HHS R01 AI140909NIAID NIH HHS U01 AI141990
6 · The paper itself

Abstract

Antibodies (Abs) are essential for the host immune response against SARS-CoV-2, and all the vaccines developed so far have been designed to induce Abs targeting the SARS-CoV-2 spike. Many studies have examined Ab responses in the blood from vaccinated and infected individuals. However, since SARS-CoV-2 is a respiratory virus, it is also critical to understand the mucosal Ab responses at the sites of initial virus exposure. Here, we examined plasma versus saliva Ab responses in vaccinated and convalescent patients. Although saliva levels were significantly lower, a strong correlation was observed between plasma and saliva total Ig levels against all SARS-CoV-2 antigens tested. Virus-specific IgG1 responses predominated in both saliva and plasma, while a lower prevalence of IgM and IgA1 Abs was observed in saliva. Antiviral activities of plasma Abs were also studied. Neutralization titers against the initial WA1 (D614G), B.1.1.7 (alpha) and B.1.617.2 (delta) strains were similar but lower against the B.1.351 (beta) strain. Spike-specific antibody-dependent cellular phagocytosis (ADCP) activities were also detected and the levels correlated with spike-binding Ig titers. Interestingly, while neutralization and ADCP potencies of vaccinated and convalescent groups were comparable, enhanced complement deposition to spike-specific Abs was noted in vaccinated versus convalescent groups and corresponded with higher levels of IgG1 plus IgG3 among the vaccinated individuals. Altogether, this study demonstrates the detection of Ab responses after vaccination or infection in plasma and saliva that correlate significantly, although Ig isotypic differences were noted. The induced plasma Abs displayed Fab-mediated and Fc-dependent functions with comparable neutralization and ADCP potencies, but a greater capacity to activate complement was elicited upon vaccination.

Indexed as

AdultAgedAntibodies, NeutralizingAntibodies, ViralAntibody FormationCOVID-19COVID-19 VaccinesFemaleHumansImmunoglobulin GMaleMiddle AgedSalivaSARS-CoV-2Spike Glycoprotein, CoronavirusVaccinationAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesImmunoglobulin GSpike Glycoprotein, CoronavirusADCPantibody isotypescomplement fixationCOVID-19neutralizationsalivaSARS-CoV-2vaccination

Identifiers

PMID34987505
PMCPMC8721203
OpenAlexW4200370751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.